Trending Topics in Gastroenterology | GastroAGI

Lean MASLD: Why Exercise Matters More Than Weight Loss: Gastroenterology | March 2026

Introduction – MASLD in Normal-Weight Individuals Metabolically dysregulated steatotic liver disease (MASLD) is commonly linked with obesity and metabolic syndrome. However, a significant subset of patients develop MASLD despite having a normal body mass index (BMI)—often referred to as lean or normal-weight MASLD. These individuals may still have metabolic abnormalities such as insulin resistance, visceral adiposity, or sedentary lifestyles. Current global MASLD guidelines recommend 3–5% weight reduction even in normal-weight individuals to reduce liver fat. However, emerging evidence suggests that focusing primarily on weight loss in this population may be misguided and clinically impractical. Why Weight Reduction May Not Help in Lean MASLD For patients already within a healthy weight range, further weight loss may provide limited metabolic benefit and can be difficult to achieve or sustain. More importantly, exercise exerts powerful liver-specific metabolic effects independent of body weight changes. Physical activity improves insulin sensitivity, enhances mitochondrial function, and increases hepatic fatty acid oxidation—mechanisms that directly reduce liver fat without requiring weight loss. Clinical studies show that structured aerobic or resistance exercise can reduce intrahepatic fat by 10–30%, even when body weight remains unchanged. Meta-analyses confirm that ≥150 minutes of moderate exercise weekly significantly improves hepatic steatosis independent of weight reduction. These findings suggest that in lean MASLD, lifestyle interventions should prioritise regular physical activity rather than weight-centric goals, reframing exercise as a direct therapeutic strategy rather than merely a tool for weight loss.

Dapagliflozin Reduces Liver Fat Independent of Weight Loss in T2D Obesity | Feb 2026 | DOI: 10.1002/oby.70134

Introduction In type 2 diabetes, hepatic steatosis is common and contributes to cardiometabolic risk. SGLT2 inhibitors improve weight and glycemia, but whether they reduce liver fat through weight loss alone or via a direct hepatic effect has remained uncertain. Summary This secondary analysis of a randomised, placebo-controlled trial studied 56 patients with type 2 diabetes assigned to placebo or dapagliflozin 10 mg for 12 months. Most participants (76%) had hepatic steatosis at baseline, and groups were comparable in metabolic risk and liver fat. Compared with placebo, dapagliflozin significantly reduced liver fat measured by MRI–proton density fat fraction (PDFF), alongside modest reductions in body weight and HbA1c. Crucially, mediation analysis showed that the reduction in liver fat was driven by a direct effect of dapagliflozin, while the indirect pathway via weight loss was not statistically significant. The findings suggest dapagliflozin can lower hepatic fat in T2D beyond its effects on weight and glycemic control, supporting further investigation of SGLT2 inhibitors as potential tools for managing metabolic dysfunction–associated steatotic liver disease.

Do Patients Want MASLD Screening? Hepatology | February 2026

Screening for metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly discussed, but concerns about anxiety, stigma, and overdiagnosis persist. This population-based study from Olmsted County evaluated how individuals perceive the benefits and harms of proactive MASLD screening. Among 461 screened participants (74% survey response rate), psychological impact was modest. Only 14% reported screening-related anxiety, and 14% were concerned about disclosing a potential diagnosis. Reassurance was substantial: 99% of participants without MASLD felt reassured about their liver health, 48% reported improved quality of life, and 25% adopted healthier lifestyle behaviours. Among 77 individuals diagnosed with MASLD, 52% experienced some anxiety; however, 95% believed early diagnosis was important to prevent cirrhosis, and 97% valued cardiovascular risk mitigation. Importantly, 79% reported the diagnosis motivated healthier habits, and 30% achieved >10% weight loss following screening. Overall, perceived benefits—including awareness, lifestyle change, and early prevention—outweighed psychological harms. Conclusion: Patient-centred MASLD screening appears acceptable and potentially empowering, supporting early detection strategies integrated with structured lifestyle interventions.

Do ACE Inhibitors and ARBs Improve Liver Outcomes in MASLD?- Hepatology Feb.26

Metabolic dysfunction–associated steatotic liver disease (MASLD) is tightly linked to cardiometabolic comorbidities, particularly hypertension. While blood pressure control is essential for cardiovascular risk reduction, whether antihypertensive drug choice influences liver-related outcomes has remained uncertain. This commentary reviews new evidence evaluating the potential role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in MASLD. Using a large U.S. insurance database and a target trial emulation approach, Ng and colleagues compared MASLD patients newly started on ACEI/ARB with those started on calcium channel blockers. The analysis suggested that ACEI/ARB use was associated with a lower risk of major adverse liver outcomes, including hepatic decompensation, as well as fewer cardiovascular events. These findings align with preclinical data showing antifibrotic effects of renin–angiotensin system inhibition and support the concept that systemic metabolic therapies may influence liver disease progression. However, important limitations temper interpretation. As with all observational studies, residual confounding cannot be excluded, and the apparent cardiovascular advantage of ACEI/ARB over calcium channel blockers contrasts with results from randomized cardiovascular trials. Differences from prior Asian cohort studies—particularly regarding hepatocellular carcinoma risk—highlight how disease definitions, competing liver etiologies, and study design can influence results. In addition, the lack of granular fibrosis markers and treatment adherence data limits causal inference. In summary, ACEI/ARB therapy may offer dual cardiovascular and hepatic benefit in MASLD, but the evidence remains indirect. Until randomized trials are available, antihypertensive selection should prioritize established cardiovascular and renal indications, within a holistic strategy to manage metabolic risk in MASLD patients.

Hypertension Accelerates Liver Disease Progression in MASLD- AJG Feb.26

Introduction Metabolically–dysfunction–associated steatotic liver disease (MASLD) frequently coexists with hypertension, yet blood pressure has traditionally been viewed mainly through a cardiovascular lens. Whether hypertension directly influences liver disease progression and long-term hepatic outcomes has remained uncertain. This large, multicohort study addresses that gap by asking a simple but important question: Does hypertension independently worsen outcomes and fibrosis progression in MASLD? What the investigators did: The authors analysed three large, complementary cohorts: A population-based cohort to assess long-term clinical outcomes (death, cardiovascular events, liver-related events). A noninvasive elastography cohort to evaluate liver stiffness progression over time. A paired liver biopsy cohort to directly measure histologic fibrosis progression. By combining population data, noninvasive markers, and histology, the study provides a uniquely robust picture of disease evolution. Key findings clinicians should understand 1) Hypertension independently worsens long-term outcomes Patients with MASLD and hypertension experienced more adverse clinical events over time—not only cardiovascular events, but also liver-related complications and mortality. 2) Hypertension accelerates liver disease progression Across two independent measures of disease activity: Liver stiffness increased faster, and Fibrosis progressed more frequently in patients with hypertension compared with those without. 3) This is not just association—it’s consistent across methods The relationship between hypertension and MASLD progression was seen: in population-level data, with noninvasive fibrosis assessment, and on paired histologic evaluation. This consistency strongly supports a true biological link, not just confounding. Why this matters clinically Hypertension is modifiable Unlike many genetic or metabolic drivers, blood pressure is treatable—making it a practical intervention point. MASLD care must be multidisciplinary These findings emphasize that optimal MASLD management requires: hepatology, cardiology, and primary care alignment. Risk stratification should change Patients with MASLD and hypertension represent a higher-risk subgroup who may benefit from: closer fibrosis monitoring, earlier use of noninvasive tools (e.g., elastography), and more aggressive cardiometabolic risk control. Pathophysiologic perspective: Hypertension may contribute to liver injury through: endothelial dysfunction, altered hepatic microcirculation, systemic inflammation, and shared metabolic pathways with insulin resistance. These mechanisms provide biologic plausibility for the observed acceleration of fibrosis. Bottom-line takeaway from GastroAGI Hypertension is not just a cardiovascular comorbidity in MASLD—it is a key, modifiable driver of liver disease progression and adverse outcomes. Blood pressure control should be a core component of MASLD management. One-line GastroAGI takeaway In MASLD, controlling blood pressure may help protect the liver as much as the heart.

ANTICIPATE-NASH Beats Biopsy for Event Risk in MASLD- Gastroenterology Feb.26

Introduction In metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis stage on liver biopsy (F3 vs F4) remains the cornerstone for prognosis, surveillance, and clinical trial eligibility. However, real-world experience tells us that not all F3 patients behave the same, and not all F4 patients decompensate. This study challenges a long-standing paradigm: Is histology really the best way to stratify risk in advanced MASLD? The clinical problem Biopsy-based fibrosis staging has important limitations: It is invasive, costly, and prone to sampling variability It provides a static snapshot, not a dynamic risk estimate It performs poorly in predicting who will actually develop clinical events At the same time, portal hypertension—not fibrosis alone—drives outcomes in advanced MASLD. What the study did: Evaluated two large multicenter cohorts of patients with biopsy-proven F3–F4 MASLD Compared traditional histologic staging with the noninvasive ANTICIPATE-NASH models, which estimate risk of: clinically significant portal hypertension liver-related clinical events (decompensation, HCC, transplant, death) Tested whether biopsy added any meaningful prognostic value beyond the models Validated findings in an independent cohort from randomised clinical trials, using regulatory endpoints Key findings clinicians should understand 1) Noninvasive models clearly outperform histology ANTICIPATE-NASH stratified the risk of liver-related events far better than F3 vs F4 on biopsy. Histology alone showed limited ability to predict outcomes. 2) Biopsy adds no incremental value once the model is known When ANTICIPATE-NASH risk was included, the fibrosis stage did not improve prediction. In other words, the model already captured what truly matters for prognosis. 3) F3 and F4 patients overlap biologically Some F3 patients had high ANTICIPATE-NASH scores and developed clinical events Some F4 patients had low scores and remained stable This highlights why the fibrosis stage alone is an unreliable surrogate for risk. 4) Results hold up in clinical trial populations The superiority of ANTICIPATE-NASH over histology was confirmed using regulatory trial endpoints, strengthening the relevance for drug development. Why this matters for daily practice Risk stratification: Surveillance, intensity of follow-up, and counselling should move beyond biopsy labels. Clinical trials: ANTICIPATE-NASH can: enrich trials with patients likely to experience events Identify patients more likely to show cirrhosis regression, improving signal detection Future care models: This supports a shift from “what stage is the biopsy?” to “What is the patient’s actual risk?” Bottom-line takeaway: In advanced MASLD, noninvasive ANTICIPATE-NASH models predict real clinical outcomes far better than the liver biopsy fibrosis stage. Histology should no longer be considered the gold standard for risk stratification in this population. One-line GastroAGI takeaway In MASLD, prognosis is driven by risk, not biopsy stage.

Noninvasive markers and Prediction of treatment with Semaglutide (AP&T) - Jan,2026

As of my training cut-off in October 2023, I do not have access to specific information about a publication titled "Noninvasive markers and Prediction of treatment with Semaglutide (AP&T) - Jan, 2026." However, I can provide a detailed overview based on the context provided above about the use of non-invasive tests for assessing treatment response to semaglutide in MASH (Metabolic Associated Steatohepatitis). ### Overview of Non-Invasive Markers and Semaglutide in MASH 1. **Liver Biopsy Limitations**: - Liver biopsy is the gold standard for assessing liver conditions like MASH but is invasive, costly, and impractical for repeated monitoring. - This has driven the need to develop reliable non-invasive tools for monitoring treatment responses. 2. **Semaglutide in MASH**: - Semaglutide, a GLP-1 receptor agonist, is being explored as a treatment for MASH. - A phase 2b trial demonstrated that semaglutide could reduce liver damage and improve histological features of the disease. 3. **Non-Invasive Tests (NITs) as Potential Biomarkers**: - The study evaluated a broad panel of serum-based, imaging-based, and composite non-invasive tests to assess their utility in monitoring treatment response to semaglutide. - Examples of these tests include liver stiffness measurement, fibrosis-related biomarkers, and other composite scores. 4. **Key Findings from the Study**: - **Early Treatment Effects**: Reductions in non-invasive test scores were observed early during semaglutide treatment. - **Consistent Improvements**: All evaluated non-invasive tests showed improvement with semaglutide compared to placebo. - **Alignment with Histology**: Improvements in non-invasive tests were generally consistent with histological improvements, suggesting their potential as surrogate markers. - **Reduced Fibrosis Worsening**: Semaglutide-treated patients demonstrated less fibrosis progression compared to those on placebo. - **Baseline Risk Stratification**: Baseline levels of non-invasive tests were associated with future fibrosis progression or improvement, highlighting their prognostic value. 5. **Prognostic Utility**: - Fibrosis-related non-invasive tests, such as liver stiffness measurement, showed particular promise due to their existing clinical application and ability to predict disease progression. - Semaglutide treatment increased the likelihood of patients moving into lower clinical risk categories as assessed by non-invasive tests. 6. **Combined NIT Approach**: - The study suggested that using multiple non-invasive tests together might improve the robustness and reliability of treatment assessments. 7. **Challenges and Limitations**: - The findings were exploratory and not adjusted for multiple comparisons. - Larger, longer-term studies are required to validate the utility of non-invasive tests as regulatory biomarkers for treatment response in MASH. 8. **Clinical Implications**: - Non-invasive tests have the potential to replace liver biopsy for monitoring treatment response in MASH. - If validated in future studies, these tests could streamline clinical trials, reduce patient burden, and facilitate broader adoption of treatments like semaglutide. 9. **Future Directions**: - Further research is needed to confirm the findings in larger cohorts and over longer durations. - Regulatory approval of non-invasive tests as biomarkers for treatment response would be a significant step forward in MASH management. If you are referring to a specific study or publication from January 2026, I recommend consulting the original source or related journals such as *Alimentary Pharmacology & Therapeutics (AP&T)* for the most up-to-date and detailed information.

HCC Risk Prediction in Chronic HBV With Metabolic Dysfunction

Hepatocellular carcinoma (HCC) risk prediction in patients with chronic hepatitis B virus (HBV) infection who also have metabolic dysfunction is a complex but crucial aspect of clinical care. This population faces a compounded risk due to the interplay of chronic HBV infection and metabolic comorbidities, such as obesity, diabetes, hypertension, and dyslipidemia. Below is a detailed breakdown of the key factors, tools, and considerations for HCC risk prediction in this unique group: --- ### **1. Dual Disease Burden** Patients with chronic HBV and metabolic dysfunction represent a high-risk group due to the combined impact of viral and metabolic factors on liver health. This dual burden increases the likelihood of liver-related complications, including cirrhosis and HCC. Effective risk prediction and management are essential to mitigate these outcomes. --- ### **2. Importance of Metabolic Comorbidities** Metabolic dysfunction-associated conditions—such as overweight, diabetes, hypertension, and dyslipidemia—are significant contributors to adverse liver outcomes in chronic HBV. These conditions exacerbate liver inflammation, fibrosis progression, and overall disease severity, thereby influencing HCC risk. --- ### **3. Role of MASLD** Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), often coexists with chronic HBV. However, MASLD itself does not independently worsen HCC risk beyond the impact of metabolic dysfunction. The presence of steatosis (fatty liver) is not a decisive factor for HCC risk once metabolic dysfunction is accounted for. --- ### **4. Key Determinants of HCC Risk** Several factors play a critical role in predicting HCC risk in chronic HBV patients with metabolic dysfunction: - **Cirrhosis:** The presence of cirrhosis is the strongest clinical indicator of HCC risk. Patients with cirrhosis require closer monitoring, even if other risk factors are minimal. - **Age:** Increasing age is consistently associated with higher HCC risk in this population. Older patients are more likely to develop liver-related complications. - **Platelet Count:** Low platelet levels reflect advanced liver disease and are linked to a higher HCC risk. - **Albumin Levels:** Reduced albumin levels indicate impaired liver function and are associated with worse outcomes. - **Metabolic Factors:** Conditions like diabetes and obesity further amplify the risk. --- ### **5. Risk Prediction Tools: PAGE-B Score** The PAGE-B score is a validated and practical tool for predicting HCC risk in patients with chronic HBV, including those with metabolic dysfunction. It incorporates key variables such as age, gender, and platelet count, making it simple and accessible for clinical use. - **Consistency Across Metabolic Conditions:** The predictive performance of the PAGE-B score remains stable across various metabolic comorbidities, reinforcing its reliability in this complex population. - **Utility Beyond HCC:** The PAGE-B score also correlates with the risk of broader liver-related events, not just HCC, making it a versatile tool. - **Low-Risk Group Identification:** Patients with low PAGE-B scores and no cirrhosis are at minimal risk of HCC and may avoid intensive surveillance, improving resource efficiency. - **Residual Risk in Cirrhosis:** Even patients with low PAGE-B scores who have cirrhosis retain a meaningful risk of HCC and require ongoing monitoring. Other risk models are available, but the PAGE-B score is favored due to its simplicity and widespread applicability. --- ### **6. Personalized Surveillance Approach** HCC risk is not uniform across all patients with chronic HBV and metabolic dysfunction. A personalized approach to risk stratification and surveillance is essential: - **High-Risk Patients:** Individuals with cirrhosis, advanced age, low platelet counts, and low albumin levels require intensive monitoring and regular imaging for early HCC detection. - **Low-Risk Patients:** Those without cirrhosis and with low PAGE-B scores may benefit from less frequent surveillance, reducing unnecessary procedures and healthcare costs. --- ### **7. Implications of Antiviral Therapy** Antiviral therapy for chronic HBV does not directly increase HCC risk. Instead, associations between antiviral therapy and outcomes reflect the underlying severity of liver disease. Effective antiviral treatment remains a cornerstone of HBV management and can help reduce long-term liver complications. --- ### **8. Addressing Metabolic Dysfunction** Managing metabolic dysfunction is an important component of reducing HCC risk in this population. Interventions targeting weight loss, glycemic control, lipid management, and blood pressure regulation may mitigate liver-related risks and improve overall outcomes. --- ### **9. Clinical Practice Relevance** The integration of metabolic assessment with established HBV risk tools, such as the PAGE-B score, enables a more comprehensive approach to HCC risk prediction. This strategy allows clinicians to: - Identify high-risk patients who need intensive surveillance. - Avoid over-monitoring low-risk individuals, optimizing healthcare resources. - Address metabolic comorbidities to reduce long-term liver complications. --- ### **Conclusion** HCC risk prediction in chronic HBV patients with metabolic dysfunction requires a nuanced approach that considers both viral and metabolic factors. Tools like the PAGE-B score provide a reliable framework for stratifying risk and guiding surveillance strategies. By integrating metabolic management into HBV care, clinicians can further reduce the burden of liver-related complications and improve patient outcomes.

Phase III Trial of Norursodeoxycholic Acid in MASLD

The Phase III trial of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) was designed to evaluate the efficacy and safety of this promising therapeutic option in a broader patient population. MASLD is a highly prevalent chronic liver condition associated with obesity, insulin resistance, diabetes, and dyslipidaemia. It progresses from simple steatosis to more severe forms like steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma, while also increasing the risk of extrahepatic complications. Despite its growing global impact, MASLD often remains asymptomatic in its early stages, and no widely approved pharmacological treatments are available. Lifestyle modifications are the primary management strategy, but long-term adherence and effectiveness are often challenging. ### Key Highlights of the Phase III Trial: 1. **Objective**: The trial aimed to evaluate whether norursodeoxycholic acid, a modified bile acid with enhanced hepatic activity and antifibrotic mechanisms, could improve liver function and noninvasive markers of fibrosis in patients with MASLD. 2. **Background**: Ursodeoxycholic acid has previously shown biochemical improvements in MASLD patients but demonstrated limited histological efficacy. Norursodeoxycholic acid, on the other hand, has shown promise in preclinical and early clinical studies due to its ability to target hepatic inflammation and fibrosis, the key drivers of disease progression. Robust Phase III evidence was needed to confirm its therapeutic role. 3. **Design**: The trial was randomized, placebo-controlled, and involved patients diagnosed with early-stage MASLD. Participants were assigned to receive norursodeoxycholic acid or a placebo over a defined period, with regular assessments of liver function, fibrosis markers, and safety parameters. 4. **Results**: - **Efficacy**: Norursodeoxycholic acid demonstrated clinically meaningful improvements in liver function and noninvasive markers of fibrosis. These results suggest its potential to slow or halt the progression of MASLD. - **Safety and Tolerability**: The drug maintained a favorable safety profile, with minimal adverse effects reported during the trial. This reinforces its suitability for long-term use in MASLD patients. 5. **Conclusion**: The findings from this Phase III trial support norursodeoxycholic acid as a promising therapeutic option for early-stage MASLD. It addresses an important unmet need by targeting hepatic inflammation and fibrosis, which are critical drivers of disease progression. The drug's safety and efficacy make it a viable candidate for routine clinical practice, especially for patients who struggle with lifestyle modifications or lack effective pharmacological treatments. ### Implications: The results of this trial mark a significant step forward in the management of MASLD. Norursodeoxycholic acid could potentially fill the gap in pharmacological treatment options for this highly prevalent condition, offering hope to millions of patients worldwide. Further studies may explore its long-term benefits, impact on advanced stages of MASLD, and potential use in combination therapies.

FIB-4 as a Referral Index for Coronary Artery Calcification in MASLD

The Fibrosis-4 (FIB-4) index has emerged as a potentially valuable tool for assessing the risk of coronary artery calcification (CAC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). This study highlights the utility of FIB-4 as a noninvasive marker that can stratify cardiovascular risk and guide clinical decision-making in MASLD patients. ### Key Findings: 1. **Association Between MASLD and CAC**: - Individuals with MASLD were found to have a higher prevalence of coronary artery calcification compared to those without MASLD. - This suggests that MASLD, which is characterized by steatotic liver disease and cardiometabolic risk factors, is closely linked to coronary atherosclerosis. 2. **Role of FIB-4 Index**: - The FIB-4 index, a simple calculation based on age, platelet count, AST (aspartate aminotransferase), and ALT (alanine aminotransferase), was used to estimate liver fibrosis severity. - Higher FIB-4 values were associated with more advanced coronary calcification, indicating a greater risk of coronary artery disease (CAD). - Conversely, lower FIB-4 values were effective in identifying individuals at low risk of severe CAC. 3. **Progressive Risk in MASLD**: - In MASLD patients, increasing liver fibrosis severity (reflected by higher FIB-4 values) corresponded with progressively higher coronary calcium levels. - This relationship underscores the interconnectedness of liver fibrosis and cardiometabolic burden in driving coronary atherosclerosis. ### Clinical Implications: - **Risk Stratification**: - FIB-4 can serve as a practical, noninvasive index to stratify cardiovascular risk in MASLD patients. Elevated FIB-4 values may identify individuals who require closer cardiovascular monitoring and intervention. - Patients with low FIB-4 scores may be considered at lower risk for severe CAC, potentially reducing the need for more invasive diagnostic procedures. - **Early Preventive Care**: - Routine use of the FIB-4 index in MASLD patients can guide early preventive measures to mitigate cardiovascular risk, including lifestyle modifications, pharmacological interventions, and closer monitoring for coronary artery disease. - **Integration in Clinical Practice**: - The FIB-4 index is inexpensive, widely accessible, and easy to calculate, making it a feasible tool for routine use in primary care and specialized settings. ### Conclusion: The study underscores the clinical utility of the FIB-4 index as a referral index for coronary artery calcification in MASLD patients. By identifying individuals at increased risk of coronary atherosclerosis, FIB-4 can help optimize cardiovascular risk stratification and facilitate early preventive care. This approach may ultimately improve long-term outcomes for patients with MASLD and associated cardiometabolic conditions.